Covid-19 manufacturing roundup: Scottish government invests $27M in Valneva's Covid-19 manufacturing; Moderna partners with Latin American pharma
Valneva’s Scottish unit has received a $27 million grant to fund the R&D of manufacturing its Covid-19 vaccine VLA2001.
The investment comes from the country’s economic development agency. Two grants will distribute the money over the next three years, and benefit the manufacturing site in Livingston.
One grant, worth $16.65 million, will support R&D connected to manufacturing VLA2001. A second, worth $9.9 million, will support R&D for the manufacturing of other diseases. Among those other vaccines is VLA1553, a single-shot vaccine against the mosquito-borne viral infection chikungunya. That is also manufactured in Livingston.
“From the only inactivated, whole virus Covid-19 vaccine candidate in clinical development in Europe to the most clinically advanced vaccine candidate against chikungunya in the world, Scottish Enterprise’s investment will support progress across Valneva’s research and development portfolio – as well as jobs and growth in Scotland,” CEO Thomas Lingelbach said in a statement.
Moderna partners with Latin American Pharma
In a move to advance the commercialization of Moderna’s Covid-19 shot in Latin America, the biotech has inked a deal with a pharma native to the continent to help make and distribute its shot.
Adium Pharma will commercialize Spikevax across 18 countries in Latin America. That list includes Brazil, Mexico, Colombia and Argentina. The company will look to add up to 100 people to its team as well.
“Our new partnership with Adium will help ensure broad access and delivery of our Moderna Covid-19 vaccine to people across Latin America,” said CEO Stéphane Bancel. “A presence in Latin America is a key part of our global commercial strategy. These partnerships and the expansion of our global commercial footprint position Moderna to play an important role in providing healthcare security against Covid-19 and future vaccine-preventable diseases.”
Moderna has only gotten emergency authorization in five of those countries so far, but Moderna’s Roman Saglio told Bloomberg that the deal, which will lead to a significant ramp up of manufacturing by Moderna, will help the company be a leading vaccine provider for the region.